Media Summary: In the following interview, conducted at the 2026 American Urological Association Annual Meeting in Washington, DC, Focus on: Non-Muscle Invasive Bladder Cancer Update for the Urology Care Team (2026) CME Available: ... Continuing his discussion at the AUA 2024 Annual Meeting, Vikram M. Narayan,

Mark Tyson Md Highlights Additional Safety Data On Durvalumab Plus Bcg In Bcg Naive Nmibc - Detailed Analysis & Overview

In the following interview, conducted at the 2026 American Urological Association Annual Meeting in Washington, DC, Focus on: Non-Muscle Invasive Bladder Cancer Update for the Urology Care Team (2026) CME Available: ... Continuing his discussion at the AUA 2024 Annual Meeting, Vikram M. Narayan, At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Noah Hahn, Dr Charalampos Fragkoulis speaks to ecancer about a phase II trial by the Hellenic GU Cancer Group. This trial investigates the ... Dr Powles talks to ecancer at the 2025 ASCO conference about

Dr Hayne talks to ecancer at ASCO 2025 about the phase 3 randomized trial ANZUP 1301 which evaluated whether combining ...

Photo Gallery

Mark Tyson, MD, highlights additional safety data on durvalumab plus BCG in BCG-naive NMIBC
Phase 1/2 trial evaluates recombinant BCG in BCG-naïve NMIBC
BOND-003 With Dr. Mark D. Tyson: Cretostimogene for BCG-Unresponsive Bladder Cancer
Sequencing Therapies in NMIBC Management w/ Dr. Mark Tyson & Dr. Suzanne Merrill | Urology Ep. 267
Focus on: Non-Muscle Invasive Bladder Cancer Update for the Urology Care Team (2026)
Urinary MRD Detection for Predicting Recurrence, Response to Nadofaragene in BCG-Unresponsive NMIBC
Treatment of High-Risk NMIBC: Is BCG Still the Best Option?
ADAPT-BLADDER Cohort 4: Durvalumab + Intravesical Gemcitabine & Docetaxel in BCG-Unresponsive NMIBC
Intravesical IO using durvalumab shows promising results for patients with high-risk NMIBC
Sasanlimab BCG combo improves outcomes in high-risk NMIBC
Emerging Treatments for BCG Unresponsive Non-muscle Invasive Bladder Cancer
CREST: Sasanlimab Plus BCG for High-Risk NMIBC
Sponsored
Sponsored
View Detailed Profile
Mark Tyson, MD, highlights additional safety data on durvalumab plus BCG in BCG-naive NMIBC

Mark Tyson, MD, highlights additional safety data on durvalumab plus BCG in BCG-naive NMIBC

In the following interview, conducted at the 2026 American Urological Association Annual Meeting in Washington, DC,

Phase 1/2 trial evaluates recombinant BCG in BCG-naïve NMIBC

Phase 1/2 trial evaluates recombinant BCG in BCG-naïve NMIBC

The phase 1/2 ResQ133A-

Sponsored
BOND-003 With Dr. Mark D. Tyson: Cretostimogene for BCG-Unresponsive Bladder Cancer

BOND-003 With Dr. Mark D. Tyson: Cretostimogene for BCG-Unresponsive Bladder Cancer

Mark

Sequencing Therapies in NMIBC Management w/ Dr. Mark Tyson & Dr. Suzanne Merrill | Urology Ep. 267

Sequencing Therapies in NMIBC Management w/ Dr. Mark Tyson & Dr. Suzanne Merrill | Urology Ep. 267

New FDA-approved therapies for

Focus on: Non-Muscle Invasive Bladder Cancer Update for the Urology Care Team (2026)

Focus on: Non-Muscle Invasive Bladder Cancer Update for the Urology Care Team (2026)

Focus on: Non-Muscle Invasive Bladder Cancer Update for the Urology Care Team (2026) CME Available: ...

Sponsored
Urinary MRD Detection for Predicting Recurrence, Response to Nadofaragene in BCG-Unresponsive NMIBC

Urinary MRD Detection for Predicting Recurrence, Response to Nadofaragene in BCG-Unresponsive NMIBC

Continuing his discussion at the AUA 2024 Annual Meeting, Vikram M. Narayan,

Treatment of High-Risk NMIBC: Is BCG Still the Best Option?

Treatment of High-Risk NMIBC: Is BCG Still the Best Option?

Neal Shore,

ADAPT-BLADDER Cohort 4: Durvalumab + Intravesical Gemcitabine & Docetaxel in BCG-Unresponsive NMIBC

ADAPT-BLADDER Cohort 4: Durvalumab + Intravesical Gemcitabine & Docetaxel in BCG-Unresponsive NMIBC

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Noah Hahn,

Intravesical IO using durvalumab shows promising results for patients with high-risk NMIBC

Intravesical IO using durvalumab shows promising results for patients with high-risk NMIBC

Dr Charalampos Fragkoulis speaks to ecancer about a phase II trial by the Hellenic GU Cancer Group. This trial investigates the ...

Sasanlimab BCG combo improves outcomes in high-risk NMIBC

Sasanlimab BCG combo improves outcomes in high-risk NMIBC

Dr Powles talks to ecancer at the 2025 ASCO conference about

Emerging Treatments for BCG Unresponsive Non-muscle Invasive Bladder Cancer

Emerging Treatments for BCG Unresponsive Non-muscle Invasive Bladder Cancer

Amirali Salmasi,

CREST: Sasanlimab Plus BCG for High-Risk NMIBC

CREST: Sasanlimab Plus BCG for High-Risk NMIBC

Neal Shore,

UROWebinar: NMIBC – BCG Unresponsive management in 2025 and new developments

UROWebinar: NMIBC – BCG Unresponsive management in 2025 and new developments

NMIBC

Treatment of high risk nMIBC in era of BCG shortage - EMPIRE Urology Lecture Series

Treatment of high risk nMIBC in era of BCG shortage - EMPIRE Urology Lecture Series

Dr. Gary Steinberg

Evaluating intravesical chemotherapy and BCG for enhanced outcomes in NMIBC

Evaluating intravesical chemotherapy and BCG for enhanced outcomes in NMIBC

Dickon Hayne, MBBS,

David Nusbaum, MD on Phase I Trial: Autologous TIL Therapy for BCG-Exposed Bladder Cancer

David Nusbaum, MD on Phase I Trial: Autologous TIL Therapy for BCG-Exposed Bladder Cancer

Join David Nusbaum,

Adaptive Immune Resistance to Intravesical BCG in NMIBC: BCG-Unresponsive Clinical Trials

Adaptive Immune Resistance to Intravesical BCG in NMIBC: BCG-Unresponsive Clinical Trials

Trinity J. Bivalacqua,

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC

Dr Hayne talks to ecancer at ASCO 2025 about the phase 3 randomized trial ANZUP 1301 which evaluated whether combining ...

Intradiscal Approach to Regenerative Therapies - Douglas P Beall, M.D.

Intradiscal Approach to Regenerative Therapies - Douglas P Beall, M.D.

Learn

Highlighting Clinical Trials: Non-Muscle Invasive Bladder Cancer | Q & A

Highlighting Clinical Trials: Non-Muscle Invasive Bladder Cancer | Q & A

In Part IV of IV of "